Our work in collaboration with the Hadden Lab on the REV7 inhibitor and mitotic sensitization of colorectal cancer cells is now available on bioRxiv: www.biorxiv.org/content/10.6...
biorxiv.org
Targeting REV7 exposes a mitotic vulnerability in colorectal cancer cells
Therapeutic resistance remains a barrier to durable treatment of colorectal cancer (CRC), highlighting the need to identify vulnerabilities in resistant tumor cells. REV7 (MAD2L2) is a multifunctional...